Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Precigen Inc (PGEN)

Precigen Inc (PGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth PR Newswire - Tue Aug 4, 3:01PM CDT

GERMANTOWN, Md. , Aug. 4, 2026 /PRNewswire/ -- Precigen, Inc.  (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 6.53 (-1.21%)
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4 PR Newswire - Tue Jul 21, 7:00AM CDT

GERMANTOWN, Md. , July 21, 2026 /PRNewswire/ -- Precigen, Inc.  (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 6.53 (-1.21%)
Financial Report by NicoElNino via Shutterstock
MoneyMasters Podcast: Where to Invest NOW in AI, Biotech, Small Caps, & Gold! MoneyShow - Thu Jul 16, 10:55AM CDT

In this timely and actionable episode, Jeffrey Hirsch, John McCamant, and Luke Lloyd discuss the best profit opportunities for the second half of 2026.

GWRE : 160.31 (+1.89%)
CLDX : 39.05 (+3.61%)
PGEN : 6.53 (-1.21%)
NVO : 44.28 (-5.97%)
AKAM : 123.35 (+4.64%)
SNEX : 75.23 (-1.26%)
ORCL : 145.74 (+2.74%)
ABBV : 243.80 (-0.53%)
GDXJ : 101.92 (+3.29%)
RSP : 220.23 (+1.44%)
VKTX : 32.94 (+1.01%)
LLY : 1,115.68 (-0.51%)
Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices PR Newswire - Thu Jun 11, 7:00AM CDT

GERMANTOWN, Md. and FORT WORTH, Texas , June 11, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative...

PGEN : 6.53 (-1.21%)
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years PR Newswire - Sat May 30, 1:30PM CDT

GERMANTOWN, Md. , May 30, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 6.53 (-1.21%)
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States PR Newswire - Wed May 27, 6:00AM CDT

GERMANTOWN, Md. , May 27, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve...

PGEN : 6.53 (-1.21%)
Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference PR Newswire - Tue May 26, 7:05AM CDT

GERMANTOWN, Md. , May 26, 2026 /PRNewswire/ -- Precigen, Inc.  (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 6.53 (-1.21%)
MarketBeat.com
Precigen Q1 Earnings Call Highlights MarketBeat - Wed May 13, 11:12PM CDT

Precigen (NASDAQ:PGEN) reported a sharp increase in first-quarter 2026 revenue as the company’s first commercial product, PAPZIMEOS, continued its U.S. launch following FDA approval in August 2025.On...

PGEN : 6.53 (-1.21%)
Precigen Reports First Quarter 2026 Financial Results and Business Updates PR Newswire - Wed May 13, 3:05PM CDT

GERMANTOWN, Md. , May 13, 2026 /PRNewswire/ --  Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 6.53 (-1.21%)
Precigen's First Commercial Quarter Will Test Whether PAPZIMEOS Revenue Can Justify the Pivot Barchart - Tue May 12, 4:09PM CDT

Barchart Research What to Expect from PGEN Earnings PGEN Generated May 12, 2026 Current Price $4.08 EPS Estimate $$-0.03 Consensus Rating Moderate Buy Average Move 9.60% Precigen's First Commercial Quarter...

PGEN : 6.53 (-1.21%)

Barchart Exclusives

Anterix Stock Has Nearly Quadrupled Over the Past Year and Could Still Go Higher Barchart - Tue Aug 4, 11:15PM CDT
Anterix (ATEX) has surged 380% over the past year, recently hitting an all-time high of $113. ATEX maintains strong technical momentum with a 100% “Buy” rating from Barchart. Revenue is forecast to grow 220.2% this year and 33.7% next year, supporting continued bullish sentiment. Valuation concerns persist, with Seeking Alpha... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.